Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)

被引:80
作者
Khan, M. S. [1 ,2 ]
El-Khouly, F. [1 ]
Davies, P. [1 ]
Toumpanakis, C. [1 ]
Caplin, M. E. [1 ]
机构
[1] Royal Free Hosp, Neuroendocrine Tumour Unit, Ctr Gastroenterol, London NW3 2QG, England
[2] UCL Canc Inst, London, England
关键词
NEUROENDOCRINE TUMORS; SOMATOSTATIN ANALOGS; GASTROENTEROPANCREATIC TUMORS; OCTREOTIDE ACETATE; ACTING FORMULATION; INTERFERON; MANAGEMENT; PATIENT; COMBINATION; PEPTIDES;
D O I
10.1111/j.1365-2036.2011.04693.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Somatostatin analogues are the mainstay of therapy for malignant carcinoid syndrome. There is clear evidence that the once monthly intramuscular formulation, Octreotide LAR, controls symptoms of carcinoid syndrome, and recent data also suggests an antitumour effect. There is limited data on prolonged release Lanreotide (Somatuline Autogel, Ipsen Pharma Biotech, Signes, France) and no long-term data to date. Aim To present long-term results of prolonged release Lanreotide in a large cohort of patients with malignant carcinoid syndrome, assessing clinical and objective response and tolerance. Methods Seventy six patients with metastatic midgut neuroendocrine tumours and carcinoid syndrome were included in this 9-year retrospective study. Clinical response was based on symptom score with radiological assessment based on RECIST (Response Evaluation Criteria In Solid Tumours). Results Data were available in 69 patients. Ninety four percent achieved symptomatic response at first follow-up visit. Forty six percent had loss of symptomatic response, but 44% of these achieved control with an increase in dose of prolonged release Lanreotide. Overall, symptoms were well controlled throughout the study period with prolonged release Lanreotide alone in 74% of patients. Twenty six percent required additional treatment despite good initial response. Only 30% demonstrated radiological progression. Eleven patients who were switched from Octreotide LAR had return of symptomatic control. No significant adverse effects were experienced. Conclusions Prolonged release Lanreotide provides good symptomatic control of diarrhoea and flushing as well as tumour stability in patients with malignant carcinoid syndrome.
引用
收藏
页码:235 / 242
页数:8
相关论文
共 31 条
[1]   Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [J].
Arnold, R ;
Trautmann, ME ;
Creutzfeldt, W ;
Benning, R ;
Benning, M ;
Neuhaus, C ;
Jurgensen, R ;
Stein, K ;
Schafer, H ;
Bruns, C ;
Dennler, HJ .
GUT, 1996, 38 (03) :430-438
[2]   Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors - A phase III study [J].
Bajetta, Emilio ;
Procopio, Giuseppe ;
Catena, Laura ;
Martinetti, Antonia ;
De Dosso, Sara ;
Ricci, Sergio ;
Lecchi, Alberto S. ;
Boscani, Paolo F. ;
Iacobelli, Stefano ;
Carteni, Giacomo ;
De Braud, Filippo ;
Loli, Paola ;
Tartaglia, Andreas ;
Bajetta, Roberto ;
Ferrari, Leonardo .
CANCER, 2006, 107 (10) :2474-2481
[3]   Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly [J].
Caron, P ;
Beckers, A ;
Cullen, DR ;
Goth, MI ;
Gutt, B ;
Laurberg, P ;
Pico, AM ;
Valimaki, M ;
Zgliczynski, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :99-104
[4]  
DAVIS GR, 1980, GASTROENTEROLOGY, V78, P346
[5]   SOMATOSTATIN INHIBITS DIARRHEA IN THE CARCINOID-SYNDROME [J].
DHARMSATHAPHORN, K ;
SHERWIN, RS ;
CATALAND, S ;
JAFFE, B ;
DOBBINS, J .
ANNALS OF INTERNAL MEDICINE, 1980, 92 (01) :68-69
[6]  
DI BM, 1996, CANCER, V77, P402
[7]   Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -: The International Lanreotide and Interferon Alfa Study Group [J].
Faiss, S ;
Pape, UF ;
Böhmig, M ;
Dörffel, Y ;
Mansmann, U ;
Golder, W ;
Riecken, EO ;
Wiedenmann, B .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2689-2696
[8]   LONG-TERM MANAGEMENT OF THE CARCINOID-SYNDROME - TREATMENT WITH OCTREOTIDE ALONE AND IN COMBINATION WITH ALPHA-INTERFERON [J].
JANSON, ET ;
OBERG, K .
ACTA ONCOLOGICA, 1993, 32 (02) :225-229
[9]   SOMATOSTATIN, GASTROINTESTINAL PEPTIDES, AND THE CARCINOID-SYNDROME [J].
LONG, RG ;
PETERS, JR ;
BLOOM, SR ;
BROWN, MR ;
VALE, W ;
RIVIER, JE ;
GRAHAMESMITH, DG .
GUT, 1981, 22 (07) :549-553
[10]   Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours [J].
Modlin, I. M. ;
Pavel, M. ;
Kidd, M. ;
Gustafsson, B. I. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (02) :169-188